TXNDC5 and prostate cancer: Inhibition of TXNDC5 expression in various cancers such as gastric cancer [39], laryngeal squamous cell carcinoma [40], non-small cell lung carcinoma [41], pancreatic cancer [42], cervical cancer [31], liver cancer [43], and castration-resistant prostate cancer [44] can provoke cell apoptosis and reduce cell proliferation and migration.